cmAngio® vs EchoSolv AS

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

cmAngio®

by CureMetrix

EchoSolv AS

by Echo IQ

AI Verdict

cmAngio® focuses on detecting Breast Arterial Calcifications from mammograms to assess cardiovascular risk, utilizing image-based AI. In contrast, EchoSolv AS analyzes numerical measurements from echocardiograms to identify patients at risk for severe aortic stenosis, providing clinical decision support. While both contribute to cardiovascular health, they address different conditions and employ distinct AI methodologies and input data types.

Choose cmAngio® if…

Choose cmAngio® if your organization aims to enhance women's cardiovascular risk assessment by leveraging existing mammography workflows. This AI software is ideal for identifying Breast Arterial Calcifications (BAC) on both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams, providing valuable insights into potential cardiovascular health risks without additional procedures. It enables proactive screening and early risk assessment within a routine breast imaging setting.

View cmAngio® →

Choose EchoSolv AS if…

Choose EchoSolv AS if your cardiology department or imaging center seeks to improve the accuracy and efficiency of identifying patients at risk for severe aortic stenosis (sAS). This AI-powered clinical decision support platform is best suited for analyzing echocardiogram measurements to provide rapid, consistent sAS probability and guideline checks. It seamlessly integrates into existing PACS workflows to streamline the detection and management of sAS.

View EchoSolv AS →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	cmAngio®	EchoSolv AS
Pricing	Paid, out-of-pocket	Unknown
Deployment	Cloud-based, integrates with any DICOM-compliant viewer	Cloud-based
BAA Available	Unknown	Yes AI-estimated
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	cmAngio®	EchoSolv AS
Name	cmAngiou00ae	EchoSolv AS
Company	CureMetrix	Echo IQ
Description	FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment.	FDA-cleared, AI-powered clinical decision support platform that analyzes echocardiograms to identify patients at risk for severe aortic stenosis with high accuracy and efficiency, integrating into existing workflows.
Primary Function	AI-based detection of Breast Arterial Calcifications (BAC)	AI-powered clinical decision support for severe aortic stenosis probability
Input Data Type	Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams	Numerical measurements (analyzes numerical measurements, not images)

Videos

Demos, reviews, and walkthroughs featuring cmAngio® and EchoSolv AS.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary clinical applications and target patient populations for cmAngiou00ae and EchoSolv AS?

cmAngiou00ae is an FDA-cleared AI software designed to detect Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment in women. EchoSolv AS is an FDA-cleared, AI-powered clinical decision support platform that analyzes echocardiograms to identify patients at risk for severe aortic stenosis.

What type of medical data do these AI tools analyze, and how do they integrate with existing imaging modalities?

cmAngiou00ae processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams, analyzing image data. EchoSolv AS is measurement-based AI, analyzing numerical measurements from echocardiograms rather than images, and is designed to integrate with PACS.

How do cmAngiou00ae and EchoSolv AS integrate into current clinical workflows?

cmAngiou00ae is compatible with any DICOM-compliant viewer and boasts quick and easy installation, typically less than an hour. EchoSolv AS is designed to fit existing workflows, integrating with PACS without requiring EMR integration.

What specific AI-driven insights or outputs do these tools provide to aid clinical decision-making?

cmAngiou00ae provides AI-based detection of BAC and visualization of BAC location on a scorecard, enabling identification and reporting without additional radiation. EchoSolv AS offers AI-powered clinical decision support for severe AS probability, consistent guideline checks from measurements, and second reader support to help prioritize studies for closer review.

What are the key technical differences in how these AI tools operate?

cmAngiou00ae directly detects and segments BAC on mammographic images and allows for an adjustable operating point to meet clinical goals. EchoSolv AS uses measurement-based AI, analyzing numerical data from echocardiograms, and notably does not use LVOT measurements for its AI analysis.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring cmAngio® or EchoSolv AS

Backers

Who funded each tool's parent company.

cmAngio®

Keshif Ventures